Robert B. Jaffe, MD

University of Michigan, Ann Arbor, 1950-53
University of Michigan, Ann Arbor, M.D., 1957, Medicine
University of Colorado, Denver, M.S., 1966, Endocrinology
Univ. of Colo. Med. Ctr., Resident, 1959-63, OB/GYN
Unite de Neuroendocrinologie, Paris, 1981, Neuroendocrinology
Peptide Biol. Lab., Salk Institute, La Jolla, CA, 1989, Neuroendocrinology/ Molecular Biology

• 1953-54
  Laboratory Assistant, Department of Biochemistry, Univ. of Michigan
• 1958-59
  USPHS Postdoctoral Fellow in Endocrinology, Dept. of Internal Medicine, Univ. of Colorado Medical Center
• 1963-64
  NIH Postdoctoral Fellow in Reproductive Endocrinology, Hormone Laboratory, Karolinska Sjukhuset, Stockholm, Sweden (Egon Diczfalusy, M.D.).
• 1964-71
  Asst and Assoc Professor of Obstetrics and Gynecology, Univ. of Michigan
• 1971-73
  Professor of Obstetrics and Gynecology, Univ. of Michigan
• 1973-present
  Professor of Obstetrics, Gynecology& Reproductive Sciences and Department of Physiology, Univ. of Calif., San Francisco School of Medicine
• 1973-95
  Chairman, Dept. of OB/GYN& Reproductive Sciences.
• 1973-00
  Director, Center for Reproductive Sciences, University of Calif., San Francisco
• 1981
  Macy Foundation Sabbatical Fellowship (C. Kordon, Ph.D.)
• 1989
  Sabbatical, Peptide Biology Laboratory, Salk Institute (W. Vale, Ph.D.)

• Alpha Omega Alpha
• USPHS (NIH) Postdoctoral Fellow in Endocrinology NIH Postdoctoral Fellow in Reproductive Endocrinology
• Josiah Macy Faculty Fellow in Obstetrics
• President, Society for Gynecologic Investigation
• President, Perinatal Research Society
• Human Embryology and Development Study Section
• Natl. Inst. of Child Health and Human Development, Advisory Council
• Josiah Macy Scholar (Neuroendocrinology)
• Assn. of American Physicians
• Reproductive Biology Study Section
• Institute of Medicine
• Fred Gellert Chair in Reproductive Medicine and Biology
• President's Distinguished Scientist Award, SGI
• Fellow, Royal College of Obstetricians and Gynaecologists, Society of Gynecological Investigation President's Mentorship Award
• Distinguished Scientist Award, American Society for Reproductive Medicine, Sidney Ingbar Distinguished Service Award, Endocrine Society

• Di Blasio AM, Cremonisi N, Vigano P, Ferrari M, Gospodarowicz D, Vignali M, Jaffe RB. Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Amer J Obstet Gynecol 169:1517, 1993
• Brandenberger AW, Tee MK, Jaffe, R.B. Estrogen receptor alpha (ER-) and beta (ER-) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER- in neoplastic tissues. J Clin Endocrinol Metab 83: 1025-1028, 1998
• Mesiano S, Ferrara N, Jaffe RB Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol, 153:1249-1256, 1998.
• Goetzl E.J, Dolezalova H, Kong Y., Hu Y-L., Jaffe, RB, Kalli KR Conover CA Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G-protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 59:5370-5375, 1999.
• Gossmann A, Helbich TH, Mesiano S, Shames DM, Wendland, MF, Roberts T.L, Ferrara N, Jaffe RB, Brasch RC Magnetic resonance imaging of altered microvascular permeability in ovarian cancer accompanying inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 183:956-963, 2000.
• Hu L, Zaloudek, C, Mills G, Gray, J, Jaffe RB In vivo and in vitro carcinoma growth inhibition by a PI3-kinase inhibitor (LY294002). Clin Cancer Res 6:880-886, 2000.
• Jaffe RB Importance of angiogenesis in reproductive physiology. Seminars in Perinatology 24:79-81, 2000.
• Goetzl EJ, Lee H, Dolezalova H, Kalli KR, Conover C A, Hu Y-L., Azuma T, Stossel TP, Karliner JS, Jaffe RB Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. New York Acad Sci. 905:177-187, 2000
• Geva E, Jaffe,R Role of vascular endothelial growth factor (VEGF) in ovarian physiology and pathology. Fertil Steril. 74:429-438, 2000
• Geva E, Jaffe RB Role of angiopoietins in reproductive tract angiogenesis. Obstet Gynecol Survey 55: 511-519, 2000
• Mills GB, Lu Y, Furui T, Shyestri L, Khan H, Fang X, Baldocchi R, Pinkel D, Cuevas B, Mao M, Jaffe R, Gray J, From genetics to therapeutic targets:Phosphatidylinositol-3'kinase (PI3K) in ovarian and breast cancer Universidad Francisco de Vitoria. M Barbacid (ed) 2000
• Mills, G., Lu, Y., Fang, X., Wang, H., Eder, A., Mao, M., Swaby, R., Cheng, K.W., Stokoe, D., Siminovitch, K., Jaffe, R. B. and Gray, J. Role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis prognosis, and therapy. Semin Oncol. Supplement July 2000.
• Lu Y, Shayestri L, Lapushin R, Yu S, Cuevas B, Fang X, Eder A, Plikoff D, Kuo WL, Baldocchi R, Vanhaesebroeck B, Pinkel D, Siminoviicitch K, Jaffe R, Gray J, Mills GB Phosphatidylinositol 3'Kinase as a Target in Selected Ovarian Cancers: From Genomics to Therapeutics. In Ovarian Cancer 6 F Sharp, T Blackett, J Berek, RC Bast (eds) 2000
• Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Weiner JR, Erickson JR, Mills GB Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer Ann NY Acad Sci 905:188-208, 2000
• Hu, Y-L., Tee, M-K., Goetzl, E.J., Auersperg, N., Mills, G.B., Ferrara, N. and Jaffe, R.B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93: 762-768, 2001.
• Tee MK, Jaffe RB A precursor form of vascular endothelial growth factor arises by initiation from an upstream in-frame CUG codon. Biochem J 359:219-226; 2001;
• Hu, L., Hofmann, J., Lu, Y., Mills, G.B. and Jaffe, R.B. Inhibition of phosphatidylinositol 3f-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087-1092, 2002.
• Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T. and Jaffe, R.B. VEGF immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161: 1917-1924, 2002
• Mills GB, Eder A, Fang X, Hasegawa,Y, Mao M, Lu Y, Tanyi J, Tabassam .H, Wiener,J, Lapushin,R, Yu S, Parrot JA, Compton T, Tribley, W, Fishman D, Stack,MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 107:259-283, 2002
• Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB . Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582:257-264, 2002
• Hu Y-L, Albanese C, Pestell RG, Jaffe RB. Dual mechanisms of lysophosphatidic acid stimulation of human ovarian cancer J Natl Cancer Inst 95:733-740. 2003
• Byrne AT, Ross L, Holash J, Nakanishi M, Yancopoulos GD, Jaffe, RB. Enforced VEGF Expression promotes ascites formation, while VEGF Trap decreases ascites formation and tumor burden in ovarian cancer models. Clin Cancer Res, 9: 5721-5728, 2003
• Evans, M.L., Pritts, E., Vittinghoff, E., McClish, K., Morgan, K.S. and Jaffe, R.B. Management of postmenopausal hot flushes with venlafaxine hydrochloride: A randomized, controlled trial. Obstet Gynecol 105: 161-166, 2005.
• Geva, E., Ginzinger, D.G., Moore, D.H., Ursell, P.C. and Jaffe, R.B. In utero angiopoietin-2 gene delivery remodels placental blood vessel phenotype: A murine model for studying placental angiogenesis. Mol Hum Reprod. 11: 253-260, 2005.
• Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 11: 8208-8212, 2005
• Hu L, Hofmann J, Holash J, Yancoupolos GD, Sood, AK, Jaffe RB. VEGF Trap combined with paclitaxel strikingly inhibit tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11: 6966-6971, 2005.